BioCentury | Jan 14, 2021
Deals

Jan. 13 Quick Takes: Takeda, KSQ enter immunotherapy deal; plus Taysha, Cardea, Esperion-Serometrix, Paion-La Jolla and more

...raised an additional $6.5 million to bring its series A round to more than $20 million. 3E Bioventures...
BioCentury | Sep 29, 2020
Financial News

Sept. 28 Quick Takes: Biogen gains $1.4B on aducanumab update; plus Zai, XtalPi, InventisBio, Galecto, Innovent, Galapagos-Gilead, Biocytogen and ACT Accelerator

...PICC Capital, SDIC Ventures, China Life Equity, 3E Bioventures...
BioCentury | Sep 10, 2020
Finance

Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma

...investor. Also participating were fellow new investors GBA Fund and GF Xinde, and existing investors 3E Bioventures...
BioCentury | Jun 17, 2020
Finance

Crossovers pile into new rounds for C4, 4D Molecular

...Perceptive. Also investing were Adage Capital Management, Axil Capital, Bain Capital Life Sciences, Commodore Capital, 3E Bioventures...
BioCentury | Mar 26, 2020
Finance

March 25 Quick Takes: Temasek leads Abbisko’s $70M C round; plus IASO and Regenacy

...a series A co-led by Cobro Ventures and Taiwania Capital Management Corp., with participation from 3E Bioventures...
BioCentury | Oct 16, 2019
Financial News

China-heavy syndicate backs $80M series B for antiviral play Ansun

...with participation by fellow existing Chinese investors Yuanming Capital, Lilly Asia Ventures, Matrix Partners China, 3E Bioventures...
BioCentury | Aug 10, 2019
Financial News

Aug. 9 Financial Quick Takes: Ironwood, Clovis, MeiraGTx, Dynavax, Biocytogen and more

...series D round led by China Life Healthcare Fund and SDIC. Prior investors CMB International, 3E Bioventures...
BioCentury | Jun 5, 2019
Finance

EpimAb raises $74M series B round to accelerate bispecific immuno-oncology pipeline expansion

...Venture Capital (SCVC) also participated, along with existing investors Oriza Seed Venture Capital, Decheng Capital, 3E Bioventures...
BioCentury | Feb 21, 2019
Emerging Company Profile

Refuge: Receptive CAR checkpoints

...partners: None Number of employees: 25 Funds raised: $37 million Investors: 3SBio Inc., Sequoia China, 3E Bioventures...
BioCentury | Aug 10, 2018
Financial News

Apexigen announces $73M in series B, C rounds

...million led by Decheng Capital, while the $58 million series C round was led by 3E Bioventures...
...funding will give the company more than two years of runway. Decheng's Dan Zabrowski and 3E Bioventures'...
Items per page:
1 - 10 of 23
BioCentury | Jan 14, 2021
Deals

Jan. 13 Quick Takes: Takeda, KSQ enter immunotherapy deal; plus Taysha, Cardea, Esperion-Serometrix, Paion-La Jolla and more

...raised an additional $6.5 million to bring its series A round to more than $20 million. 3E Bioventures...
BioCentury | Sep 29, 2020
Financial News

Sept. 28 Quick Takes: Biogen gains $1.4B on aducanumab update; plus Zai, XtalPi, InventisBio, Galecto, Innovent, Galapagos-Gilead, Biocytogen and ACT Accelerator

...PICC Capital, SDIC Ventures, China Life Equity, 3E Bioventures...
BioCentury | Sep 10, 2020
Finance

Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma

...investor. Also participating were fellow new investors GBA Fund and GF Xinde, and existing investors 3E Bioventures...
BioCentury | Jun 17, 2020
Finance

Crossovers pile into new rounds for C4, 4D Molecular

...Perceptive. Also investing were Adage Capital Management, Axil Capital, Bain Capital Life Sciences, Commodore Capital, 3E Bioventures...
BioCentury | Mar 26, 2020
Finance

March 25 Quick Takes: Temasek leads Abbisko’s $70M C round; plus IASO and Regenacy

...a series A co-led by Cobro Ventures and Taiwania Capital Management Corp., with participation from 3E Bioventures...
BioCentury | Oct 16, 2019
Financial News

China-heavy syndicate backs $80M series B for antiviral play Ansun

...with participation by fellow existing Chinese investors Yuanming Capital, Lilly Asia Ventures, Matrix Partners China, 3E Bioventures...
BioCentury | Aug 10, 2019
Financial News

Aug. 9 Financial Quick Takes: Ironwood, Clovis, MeiraGTx, Dynavax, Biocytogen and more

...series D round led by China Life Healthcare Fund and SDIC. Prior investors CMB International, 3E Bioventures...
BioCentury | Jun 5, 2019
Finance

EpimAb raises $74M series B round to accelerate bispecific immuno-oncology pipeline expansion

...Venture Capital (SCVC) also participated, along with existing investors Oriza Seed Venture Capital, Decheng Capital, 3E Bioventures...
BioCentury | Feb 21, 2019
Emerging Company Profile

Refuge: Receptive CAR checkpoints

...partners: None Number of employees: 25 Funds raised: $37 million Investors: 3SBio Inc., Sequoia China, 3E Bioventures...
BioCentury | Aug 10, 2018
Financial News

Apexigen announces $73M in series B, C rounds

...million led by Decheng Capital, while the $58 million series C round was led by 3E Bioventures...
...funding will give the company more than two years of runway. Decheng's Dan Zabrowski and 3E Bioventures'...
Items per page:
1 - 10 of 23